Skip to main content
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1995 Mar;40(2):103–108. doi: 10.1007/BF01520291

The induction of bacillus-Calmette-Guérin-activated killer cells requires the presence of monocytes and T-helper type-1 cells

Andreas Thanhäuser 1, Andreas Böhle 2, Berthold Schneider 2, Norbert Reiling 1, Taila Mattern 1, Martin Ernst 1, Hans-Dieter Flad 1, Artur J Ulmer 1,
PMCID: PMC11037779  PMID: 7882379

Abstract

Previously we have described the induction of MHC-unrestricted killer cells against bladder tumour cells by bacillus Calmette-Guérin (BCG), termed BCG-activated killer (BAK) cells. In the present paper we deal with the accessory-cell requirement for the activation of BAK cells. We show that monocytes are required for activating BAK cells, since no cytotoxicity can be induced in the absence of monocytes. Therefore, these phagocytes may represent the first step during the activation cascade of BAK cells. Furthermore, the presence of CD4+ T cells was essential for generating BAK cells: depleting peripheral blood mononuclear cells of CD4 cells prior to stimulation with BCG abolished the cytotoxicity against bladder tumour cells. Experiments with monoclonal antibodies (mAb) neutralizing the activity of either interleukin-2 (IL-2) or interferon γ (IFNγ) underlined the importance of these cytokines: both mAb blocked the induction of BAK cells. Since both cytokines are related to the so-called Th1 pattern of T cells, we consider the second step of the generation of BAK cells as follows: monocytes presenting antigens of BCG trigger Th1-like cells in a preferred manner. These Th1-like T cells secrete IL-2 and IFNγ and, thus, activate the BAK effector cells. Since CD4+ cells are dominant in the cells infiltrating the bladder wall after intravesical instillation of BCG in vivo, we postulate an important role for the Th1 subpopulation. We further postulate that the occurrence of macrophages in this infiltrate seems to be significant in the maintenance of the relapse-free state of the patient.

Key words: BCG, BAK cells, Monocytes, T-helper cells, Bladder tumour, Macrophages, NK cells

References

  • 1.de Boer EC, de Jong WH, Steerenberg PA, Aarden LA, Tetteroo E, de Groot ER, van der Meijden APM, Vegt PDJ, Debruyne FMJ, Ruitenberg EJ. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumor necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer. Cancer Immunol Immunother. 1992;34:306. doi: 10.1007/BF01741551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Böhle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad H-D. Effects of local BCG therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol. 1990;144:53. doi: 10.1016/s0022-5347(17)39365-5. [DOI] [PubMed] [Google Scholar]
  • 3.Böhle A, Nowe CH, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG, Flad H-D. Elevations of cytokines interleukin-1, interleukin-2, and tumor necrosis factor in the urine of patients following intravesical BCG immunotherapy. J Urol. 1990;144:59. doi: 10.1016/s0022-5347(17)39366-7. [DOI] [PubMed] [Google Scholar]
  • 4.Böhle A, Thanhäuser A, Ulmer AJ, Ernst M, Flad H-D, Jocham D. Dissecting the immunobiological effects of bacillus Calmette-Guérin (BCG) in-vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J Urol. 1993;150:1932. doi: 10.1016/s0022-5347(17)35941-4. [DOI] [PubMed] [Google Scholar]
  • 5.van der Bosch J, Rüller S, Horn D, Schumann R, Schlaak M. Density-dependent tumor cell death and reversible cell cycle arrest: mutually exclusive modes of monocyte-mediated growth control. Exp Cell Res. 1990;187:185. doi: 10.1016/0014-4827(90)90080-t. [DOI] [PubMed] [Google Scholar]
  • 6.Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Lab Clin Invest. 1968;21:77. [PubMed] [Google Scholar]
  • 7.Chapman PB, Houghton AN. Non-antibody immunotherapy of cancer. Curr Opin Immunol. 1993;5:726. doi: 10.1016/0952-7915(93)90128-f. [DOI] [PubMed] [Google Scholar]
  • 8.Cher DJ, Mosmann TR. Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by Th1 clones. J Immunol. 1985;138:3688. [PubMed] [Google Scholar]
  • 9.Ennen J, Ernst M, Flad H-D. The effect of interleukin 2 on Fe-gamma receptor function of human monocytes requires specific intercellular interaction. Immunobiology. 1989;179:17. doi: 10.1016/s0171-2985(89)80004-x. [DOI] [PubMed] [Google Scholar]
  • 10.Ernst M, Lange A, Flad H-D, Havel A, Ennen J, Ulmer AJ. Dissociation of responses measured by natural cytotoxicity and chemiluminescence. Eur J Immunol. 1984;14:634. doi: 10.1002/eji.1830140710. [DOI] [PubMed] [Google Scholar]
  • 11.Grage-Griebenow E, Lorenzen D, Fetting R, Flad H-D, Ernst M. Phenotypical and functional characterization of FCτ receptor I (CD64)-negative monocytes, a minor human monocyte subpopulation with high acessory and antiviral activity. Eur J Immunol. 1993;23:3126. doi: 10.1002/eji.1830231213. [DOI] [PubMed] [Google Scholar]
  • 12.Jackson AM, Prescott S, Hawkyard SJ, James K, Chisholm GD. The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical Evans BCG therapy. Cancer Immunol Immunother. 1993;36:25. doi: 10.1007/BF01789127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Julius MH, Simpson E, Herzenberg LA. A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur J Immunol. 1973;3:645. doi: 10.1002/eji.1830031011. [DOI] [PubMed] [Google Scholar]
  • 14.Phillips JH, Lanier LL. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med. 1986;164:814. doi: 10.1084/jem.164.3.814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol. 1990;144:1248. doi: 10.1016/s0022-5347(17)39713-6. [DOI] [PubMed] [Google Scholar]
  • 16.Ratliff TL, Gillen D, Catalona WJ. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol. 1987;137:155. doi: 10.1016/s0022-5347(17)43909-7. [DOI] [PubMed] [Google Scholar]
  • 17.Ratliff TL, Palmer JO, McGarr JA, Brown EJ. Intravesical BCG therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of BCG. Cancer Res. 1987;47:1762. [PubMed] [Google Scholar]
  • 18.Ratliff TL, Hudson MA, Catalona WJ. Strategy for improving therapy of superficial bladder cancer. World J Urol. 1991;9:95. [Google Scholar]
  • 19.Ratliff TL, Ritchey JK, Yuan JJJ, Andriole GL, Catalona WJ. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol. 1993;150:1018. doi: 10.1016/s0022-5347(17)35678-1. [DOI] [PubMed] [Google Scholar]
  • 20.Rieneck K, Diamant M, Haahr P-M, Schönharting M, Bendtzen K. In vitro immunomodulatory effects of pentoxifylline. Immunol Lett. 1993;37:131. doi: 10.1016/0165-2478(93)90022-t. [DOI] [PubMed] [Google Scholar]
  • 21.Rosenberg SA. Lymphokine activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst. 1985;75:595. [PubMed] [Google Scholar]
  • 22.Rott O, Cash E, Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1-but not type 2-associated lymphokine production, prevents induction of autoimmune encephalomyelitis in Lewis rats. Eur J Immunol. 1993;23:1745. doi: 10.1002/eji.1830230802. [DOI] [PubMed] [Google Scholar]
  • 23.Schur PH, Chang D-M, Baptiste P, Uhteg LC, Hanson DC. Human monocytes produce IL-1 and an inhibitor of IL-1 in response to different signals. Clin Immunol Immunopathol. 1990;57:45. doi: 10.1016/0090-1229(90)90021-h. [DOI] [PubMed] [Google Scholar]
  • 24.Thanhäuser A, Böhle A, Flad H-D, Ernst M, Mattern T, Ulmer AJ. Induction of bacillus-Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cell against human bladder carcinoma cells lines in vitro. Cancer Immunol Immunother. 1993;37:105. doi: 10.1007/BF01517042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Thanhäuser A, Reiling N, Böhle A, Toellner K-M, Duchrow M, Scheel D, Schlüter C, Ernst M, Flad H-D, Ulmer AJ. Pentoxifylline: a potent inhibitor of IL-2 and IFN-gamma biosynthesis and BCG-induced cytotoxicity. Immunology. 1993;80:151. [PMC free article] [PubMed] [Google Scholar]
  • 26.Tilg H, Eibl B, Pichl M, Gächter A, Herold M, Branova J, Huber C, Niederwieser D. Immune response modulation by pentoxifylline in vitro. Transplantation. 1993;56:196. doi: 10.1097/00007890-199307000-00036. [DOI] [PubMed] [Google Scholar]
  • 27.Wang M-H, Flad H-D, Böhle A, Chen Y-Q, Ulmer AJ. Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines. Immunol Lett. 1991;27:191. doi: 10.1016/0165-2478(91)90150-9. [DOI] [PubMed] [Google Scholar]
  • 28.Wang M-H, Chen Y-Q, Schlüter C, Arnoldi J, Gercken J, Ernst M, Gerdes J, Flad H-D, Böhle A, Ulmer AJ. Specific activation of human peripheral blood gamma/delta+ T lymphocytes by sonicated antigens ofMycobacterium tuberculosis: role in vitro in killing human bladder carcinoma cells lines. Scand J Immunol. 1993;38:239. doi: 10.1111/j.1365-3083.1993.tb01720.x. [DOI] [PubMed] [Google Scholar]
  • 29.Zabel P, Leimenstoll G, Schröder P, Elfeldt R, Schlaak M, Niedermayer W. Pentoxifylline suppresses OKT3-induced tumor necrosis factor alpha formation in renal transplant recipients. Z Tx Med. 1991;3:62. [PubMed] [Google Scholar]
  • 30.Zabel P, Wolter DT, Schönharting MM, Schade U. Oxpentifylline in endotoxaemia. Lancet. 1989;23/30:1474. doi: 10.1016/s0140-6736(89)92929-2. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES